Norges Bank
CRSP icon

Norges Bank’s CRISPR Therapeutics CRSP Stock Holding History

Norges Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Buy
+270,756
New +$14.3M ﹤0.01% 1247
2026
Q1 		– Sell
-490,206
Closed -$25.7M – 340
2025
Q4 		$25.7M Buy
+490,206
New +$29.4M ﹤0.01% 1193
2025
Q3 		– Sell
-406,487
Closed -$19.8M – 378
2025
Q2 		$19.8M Sell
406,487
-49,573
-11% -$1.92M ﹤0.01% 1190
2025
Q1 		$15.5M Buy
456,060
+12,524
+3% +$531K ﹤0.01% 1227
2024
Q4 		$17.5M Buy
443,536
+31,928
+8% +$1.51M ﹤0.01% 1254
2024
Q3 		$19.3M Sell
411,608
-238,600
-37% -$12.1M ﹤0.01% 1230
2024
Q2 		$35.1M Buy
650,208
+59,940
+10% +$3.47M 0.01% 1050
2024
Q1 		$40.2M Sell
590,268
-27,318
-4% -$1.96M 0.01% 1041
2023
Q4 		$38.7M Buy
617,586
+31,286
+5% +$1.73M 0.01% 1024
2023
Q3 		$26.6M Buy
586,300
+9,267
+2% +$479K 0.01% 1113
2023
Q2 		$32.4M Sell
577,033
-52,619
-8% -$2.99M 0.01% 1058
2023
Q1 		$28.5M Sell
629,652
-85,776
-12% -$4.17M 0.01% 1099
2022
Q4 		$29.1M Buy
715,428
+48,660
+7% +$2.58M 0.01% 1096
2022
Q3 		$43.6M Buy
666,768
+76,191
+13% +$5.52M 0.01% 829
2022
Q2 		$35.9M Sell
590,577
-23,256
-4% -$1.37M 0.01% 940
2022
Q1 		$38.5M Buy
613,833
+21,096
+4% +$1.32M 0.01% 1025
2021
Q4 		$44.9M Sell
592,737
-72,870
-11% -$6.37M 0.01% 1007
2021
Q3 		$74.5M Buy
665,607
+41,517
+7% +$5.21M 0.02% 742
2021
Q2 		$101M Buy
624,090
+67,829
+12% +$8.25M 0.02% 640
2021
Q1 		$67.8M Sell
556,261
-6,830
-1% -$1.03M 0.02% 798
2020
Q4 		$86.2M Sell
563,091
-9,296
-2% -$1.1M 0.02% 656
2020
Q3 		$47.9M Buy
572,387
+73,909
+15% +$6.56M 0.01% 860
2020
Q2 		$36.6M Buy
498,478
+335,761
+206% +$19.6M 0.01% 1050
2020
Q1 		$6.9M Buy
162,717
+142,557
+707% +$7.36M ﹤0.01% 1742
2019
Q4 		$1.23M Hold
20,160
– – ﹤0.01% 2010
2019
Q3 		$826K Buy
+20,160
New +$963K ﹤0.01% 2043

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Norges Bank's CRSP Position: Q2 2026 in Review

Norges Bank opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 270,756 shares worth $14.8M. The stake represents ﹤0.01% of the portfolio and ranks #1247 among its holdings. This is a return to the name: Norges Bank previously reported a position in CRSP as recently as Q4 2025.

Norges Bank first reported a position in CRSP in Q3 2019 and has held it in 26 quarters since. The position peaked at $101M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Norges Bank held 270,756 shares of CRISPR Therapeutics worth $14.8M as of Q2 2026.
  • CRISPR Therapeutics was a new Norges Bank position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Norges Bank's portfolio in Q2 2026, its #1247 holding.
  • Norges Bank first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 26 quarters since.
  • Norges Bank's CRISPR Therapeutics position peaked at $101M in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Norges Bank's 13F filing for Q2 2026, filed 12 Aug 2026.